Shape memory hemostasis and bone repair integrated frozen gel
By preparing a cryogel crosslinked with polysaccharides and inorganic nanofibers, the problems of poor hemostasis and bone repair needs in complex bone bleeding sites were solved, achieving an integrated effect of rapid hemostasis and bone regeneration.
Patent Information
- Application Number
- CN202511711584.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-11-20
- Publication Date
- 2026-01-20
AI Technical Summary
Existing hemostatic materials have limited effectiveness in stopping bleeding at complex bone sites and are difficult to meet the needs of bone repair. Traditional materials may cause thermal damage or local inflammatory reactions.
The shape memory cryogel, which integrates hemostasis and bone repair, is composed of polysaccharide solution, inorganic nanofibers, and cross-linking agents. It forms a three-dimensional porous structure through freeze cross-linking and drying, and combined with the bioactivity of inorganic nanofibers, it achieves rapid hemostasis and bone repair.
It achieves rapid hemostasis and promotes bone tissue repair, possesses good biocompatibility and mechanical properties, and is suitable for hemostasis and regeneration of complex bone defects.
Smart Images

Figure CN121360265A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application belongs to the field of biomedical materials, and particularly relates to a shape memory hemostatic bone repair integrated cryogel and a preparation method and application thereof. BACKGROUND
[0002] Bone tissue is a highly vascularized connective tissue, which is prone to massive bleeding in trauma or surgery, especially in blood-rich parts such as the spine and pelvis, where the amount of bleeding is more significant. Bone bleeding not only seriously affects the visibility of the surgical field, but also can cause complications such as tissue ischemia and necrosis, hemorrhagic shock, and even life-threatening.
[0003] Currently, clinical hemostatic methods such as electrocoagulation and electrocautery can achieve hemostasis in a short time, but they rely on high-temperature operation and may cause thermal injury, affecting tissue healing and delaying bone regeneration. Traditional bone wax materials can achieve hemostasis by physically sealing the bleeding site, but their non-degradable nature can easily cause local inflammatory reactions and infection risks, limiting their clinical application.
[0004] Existing absorbable hemostatic materials such as oxidized regenerated cellulose, gelatin sponge, and collagen-based materials mainly achieve hemostasis by absorbing liquid, swelling, and forming pressure on the wound surface. However, such materials have limited hemostatic effect in complex bone wounds, especially in cavity-type or difficult-to-compress areas, and their degradation rate often does not match the bone repair process, making it difficult to simultaneously meet the needs of hemostasis and tissue regeneration.
[0005] Therefore, there is an urgent need in the art for a bone repair and hemostatic material that can address the dual challenges of complex bone bleeding treatment and bone tissue repair. SUMMARY
[0006] The present application discloses a shape memory hemostatic bone repair integrated cryogel and a preparation method thereof. The gel has excellent mechanical properties, rapid hemostatic ability, and the function of promoting bone tissue repair, and is suitable for hemostasis and regeneration of complex bone defects.
[0007] In a first aspect of the present application, a preparation method of a cryogel is provided, comprising the following steps: (s1) mixing a polysaccharide solution, inorganic nanofibers, and a crosslinking agent to form a cryogel precursor solution; (s2) freezing and crosslinking the cryogel precursor solution obtained in step (s1) at low temperature to obtain a cryogel precursor; (s3) freeze-drying the cryogel precursor obtained in step (s2) to obtain the cryogel.
[0008] In another preferred embodiment, in the polysaccharide solution, the polysaccharide is selected from the group consisting of starch, hyaluronic acid, chitosan, sodium alginate, sodium carboxymethylcellulose, carboxymethylcellulose, or a combination thereof.
[0009] In another preferred embodiment, in the polysaccharide solution, the polysaccharide is chitosan.
[0010] In another preferred embodiment, in step (s1), the polysaccharide solution is prepared by dissolving a polysaccharide in a first solvent, wherein the first solvent is water or an acidic solution.
[0011] In another preferred embodiment, the water is deionized water.
[0012] In another preferred embodiment, the acidic solution is a solution of an acid.
[0013] In another preferred embodiment, in the acidic solution, the acid is selected from the group consisting of sulfuric acid, hydrochloric acid, phosphoric acid, acetic acid, lactic acid, p-hydroxybenzoic acid, glycolic acid, adipic acid, or a combination thereof.
[0014] In another preferred embodiment, in the acidic solution, the concentration of the acid is 1-10% (v / v), for example 2% (v / v).
[0015] In another preferred embodiment, the pH of the acidic solution is 2-6.8, preferably 3-6.
[0016] In another preferred embodiment, the pH of the polysaccharide solution is 2-6.8, preferably 3-6.
[0017] In another preferred embodiment, in step (s1), the mass fraction of the polysaccharide in the cryogel precursor solution is 0.1%-5% (w / v).
[0018] In another preferred embodiment, in step (s1), the ratio of the polysaccharide to the inorganic nanofiber is 1:0.1-1:1 (w / w), preferably 1:0.1-1:0.5 (w / w).
[0019] In another preferred embodiment, in step (s1), the inorganic nanofiber is a one-dimensional inorganic nanofiber having a nanostructure and a biomineralization activity.
[0020] In another preferred embodiment, in step (s1), the inorganic nanofiber is selected from the group consisting of hydroxyapatite nanowires, silicate nanowires, zirconia nanowires, titanate nanowires, magnesium-based nanowires, zinc-based nanowires, or a combination thereof.
[0021] In another preferred embodiment, in step (s1), the diameter of the inorganic nanofiber is 5-300 nm, preferably 10-100 nm.
[0022] In another preferred embodiment, in step (s1), the length of the inorganic nanofiber is 0.1-10 μm, preferably 0.5-10 μm, and again preferably 1-5 μm.
[0023] In another preferred embodiment, in step (s1), the cross-linking agent is selected from the group consisting of glutaraldehyde, terephthaldehyde, dextran aldehyde, acryloyloxy succinimidyl ester, or a combination thereof.
[0024] In another preferred embodiment, in step (s1), the cross-linking agent is 0.1%-5% of the mass of the polysaccharide.
[0025] In another preferred embodiment, in step (s1), the mass fraction of the cross-linking agent in the frozen gel precursor solution is 0.01%-5% (w / v), preferably 0.01%-1% (w / v), and more preferably 0.01%-0.5% (w / v).
[0026] In another preferred embodiment, step (s1) comprises: providing a polysaccharide solution, slowly adding inorganic nanofibers to the polysaccharide solution, adding a cross-linking agent after mixing, and rapidly stirring to form a frozen gel precursor solution.
[0027] In another preferred embodiment, the mixing comprises ultrasonic dispersion.
[0028] In another preferred embodiment, step (s1) is performed at room temperature, preferably at 5-35°C.
[0029] In another preferred embodiment, in step (s2), the freezing cross-linking comprises freezing at -10°C to -70°C (preferably -20°C to -40°C) for 12-48 h.
[0030] In another preferred embodiment, in step (s3), the freeze-drying comprises drying in a vacuum freeze-drying device or in a freeze-drying device for 24-96 h, preferably 48-72 h.
[0031] In another preferred embodiment, the inorganic nanofiber is prepared by a method comprising: (a) mixing methanol, water, and oleic acid to form a milky mixed solution, then mixing with a base to adjust the pH value, and then adding a precursor to perform a hydrothermal reaction to obtain the inorganic nanofiber.
[0032] In another preferred embodiment, in step (a), the precursor is added in the form of a precursor solution.
[0033] In another preferred embodiment, in step (a), the precursor is an inorganic salt precursor selected from the group consisting of a calcium source, a phosphorus source, a silicon source, a magnesium source, a zinc source, a titanium source, a zirconium source, or a combination thereof.
[0034] In another preferred embodiment, the calcium source is selected from the group consisting of calcium chloride, calcium nitrate, calcium acetate, or a combination thereof.
[0035] In another preferred embodiment, the phosphorus source is selected from the group consisting of sodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate (e.g., sodium dihydrogen phosphate dihydrate), ammonium phosphate, diammonium hydrogen phosphate, ammonium dihydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, or a combination thereof.
[0036] In another preferred embodiment, the silicon source is selected from the group consisting of sodium silicate, potassium silicate, or a combination thereof.
[0037] In another preferred embodiment, the magnesium source is selected from the group consisting of magnesium chloride, magnesium nitrate, magnesium bromide, magnesium acetate, or a combination thereof.
[0038] In another preferred embodiment, the titanium source is selected from the group consisting of titanium chloride, sodium hexafluorotitanate, potassium hexafluorotitanate, titanyl sulfate, or a combination thereof.
[0039] In another preferred embodiment, the zinc source is selected from the group consisting of zinc chloride, zinc sulfate, zinc nitrate, zinc perchlorate, zinc gluconate, zinc acetate, or a combination thereof.
[0040] In another preferred embodiment, the zirconium source is selected from the group consisting of zirconium chloride, zirconium oxychloride, zirconium nitrate, zirconium citrate, zirconium lactate, or a combination thereof.
[0041] In another preferred embodiment, in step (a), the precursor comprises a first precursor, a second precursor, and optionally a third precursor.
[0042] In another preferred embodiment, in step (a), the precursor solution comprises a first precursor solution, a second precursor solution, and optionally a third precursor solution.
[0043] In another preferred embodiment, the first precursor is a calcium source.
[0044] In another preferred embodiment, the second precursor, the third precursor are each independently selected from the group consisting of a phosphorus source, a silicon source, a magnesium source, a zinc source, a titanium source, a zirconium source.
[0045] In another preferred embodiment, in the first precursor solution, the concentration of the first precursor is 0.05M-1M, preferably 0.1M-0.5M, more preferably 0.1M-0.3M.
[0046] In another preferred embodiment, in the second precursor solution, the concentration of the second precursor is 0.05M-1M, preferably 0.1M-0.5M.
[0047] In another preferred embodiment, in the third precursor solution, the concentration of the third precursor is 0.05M-1M, preferably 0.1M-0.5M, more preferably 0.1M-0.3M.
[0048] In another preferred embodiment, in step (a), the concentration of the first precursor in the system is 0.005M-0.1M, preferably 0.01M-0.08M, more preferably 0.02M-0.05M.
[0049] In another preferred embodiment, in step (a), the concentration of the second precursor in the system is 0.005M-0.1M, preferably 0.01M-0.1M.
[0050] In another preferred embodiment, in step (a), the concentration of the third precursor in the system is 0.005M-0.1M, preferably 0.01M-0.08M, more preferably 0.02M-0.05M.
[0051] In another preferred embodiment, in step (a), the molar ratio of the first precursor, the second precursor, and the optional third precursor is 1:(0.1-5):(0.1-5), preferably 1:(0.3-3):(0.3-3).
[0052] In another preferred embodiment, the molar ratio of the calcium source and the phosphorus source in the reaction system is 0.5-2:0.5-2, preferably 1-2:1-2, more preferably 1:1-2.
[0053] In another preferred embodiment, in step (a), the base is selected from the group consisting of sodium hydroxide, potassium hydroxide, aqueous ammonia, sodium carbonate, sodium bicarbonate, or a combination thereof.
[0054] In another preferred embodiment, in step (a), the pH is adjusted to 7.5-12, preferably 8-11, using a base.
[0055] In another preferred embodiment, in step (a), the volume ratio of the methanol, the oleic acid, and the water is 1:0.5-2.5:0.5-2.5, preferably 1:1-2.5:1-2.5.
[0056] In another preferred embodiment, in step (a), the amount of the base added is 0.01-0.08 g / mL, preferably 0.02-0.05 g / mL, of the total volume of the system.
[0057] In another preferred embodiment, in step (a), the hydrothermal reaction is carried out at 80-250°C, preferably 120-200°C, for example 140°C-180°C.
[0058] In another preferred embodiment, in step (a), the reaction time of the hydrothermal reaction is 8-48 h, preferably 12-24 h.
[0059] In another preferred embodiment, the reaction comprises: (a) mixing methanol and oleic acid, stirring, slowly adding water to form a milky mixture, then adding a base to adjust the pH value, and then adding a precursor solution, mixing uniformly, and then transferring to a high-pressure reactor for hydrothermal reaction to obtain the inorganic nanofiber.
[0060] In a second aspect of the present application, a cryogel prepared using the method of the first aspect of the present application is provided.
[0061] In another preferred embodiment, the cryogel has a shape memory function.
[0062] In another preferred embodiment, the cryogel is a shape memory hemostatic and bone repair integrated cryogel.
[0063] In another preferred embodiment, in the cryogel, the polysaccharide, inorganic nanofiber and crosslinking agent form an interpenetrating network with each other.
[0064] In another preferred embodiment, in the cryogel, the inorganic nanofiber and the polysaccharide molecules are combined by electrostatic interaction, hydrogen bond, coordination or other non-covalent bond.
[0065] In another preferred embodiment, the cryogel has a three-dimensional porous network structure with a pore size ranging from 10 to 300 microns, preferably 50-200 μm, for example 40 μm, 60 μm, 80 μm, 100 μm, 150 μm, 200 μm.
[0066] In another preferred embodiment, the cryogel restores to the original shape within 10 s (preferably within 8 s, more preferably within 5 s, and more preferably within 3 s) after contacting a liquid (such as water, blood, serum or plasma), and has a fast response shape memory function.
[0067] In another preferred embodiment, the cryogel can be injected into the bleeding site and / or the site requiring bone repair by a syringe.
[0068] In another preferred embodiment, the cryogel can absorb exudate and guide blood cell adhesion and platelet activation through its porous structure and surface functional groups.
[0069] In another preferred embodiment, the number of blood cells adhered to the cryogel is increased by more than 2 times, preferably more than 3 times, and more preferably more than 5 times, compared to gelatin sponge.
[0070] In another preferred embodiment, the number of platelets adhered to the cryogel is increased by more than 2 times, preferably more than 3 times, and more preferably more than 5 times, compared to gelatin sponge.
[0071] In another preferred embodiment, the freeze gel has one or more of the following characteristics: 1) the average pore size of the freeze gel is 50-200 μm, preferably 80-120 μm; 2) the porosity of the freeze gel is 70%-95%, preferably 90%-95%; 3) the compressive strength of the freeze gel is 100-200 kPa, preferably 120-180 kPa; 4) the shape recovery time of the freeze gel in blood is 10 s or less, preferably 5 s or less; 5) the shape recovery rate of the freeze gel in blood is 80% or more, preferably 90% or more; 6) the recovery loss of the freeze gel after 50 cycles of compression is not more than 20%, preferably not more than 10%; 7) the coagulation index of the freeze gel is 20% or less in 5 min; 8) the adhesion efficiency of the freeze gel to blood cells is >50%, preferably >60%; 9) the amount of blood loss of the freeze gel in a rat liver perforation wound model hemostasis experiment is 45% of that of medical gelatin hemostatic sponge, preferably 30%; 10) the freeze gel can significantly promote osteoblast proliferation and differentiation after participating in hemostasis.
[0072] In a third aspect of the present application, a medical material is provided, comprising the freeze gel of the second aspect of the present application.
[0073] In another preferred embodiment, the medical material further comprises a carrier acceptable in the field of medical materials.
[0074] In another preferred embodiment, the carrier acceptable in the field of medical materials comprises one or more of a bacteriostatic agent, an antioxidant, a preservative, a buffer, a transdermal enhancer, and a stabilizer.
[0075] In a fourth aspect of the present application, the freeze gel of the second aspect of the present application or the medical material of the third aspect of the present application is used in the preparation of a medical material, which is (a) used for hemostasis; and / or (b) used for bone tissue defect repair; and / or (c) used as a controllable release carrier of a drug or a growth factor.
[0076] In another preferred embodiment, the hemostasis comprises hemostasis in complex wounds, hemostasis in narrow and deep open wounds, and hemostasis in tissue perforation injuries.
[0077] In another preferred embodiment, the drug comprises an antibacterial drug.
[0078] It should be understood that the above technical features of the present application and the technical features specifically described below (such as the examples) can be combined with each other to form new or preferred technical solutions within the scope of the present application. Due to the limited space, they will not be repeated one by one here. BRIEF DESCRIPTION OF DRAWINGS
[0079] Figure 1 SEM images of the internal structure of the freeze gel prepared in the present application.
[0080] Figure 2 Water-triggered shape memory diagram and quantitative results of the freeze gel prepared in the present application.
[0081] Figure 3 Blood-triggered shape memory diagram and quantitative results of the freeze gel prepared in the present application.
[0082] Figure 4 In vivo and in vitro biocompatibility results of the freeze gel prepared in the present application.
[0083] Figure 5 Red blood cell adhesion electron microscope images of the freeze gel prepared in the present application.
[0084] Figure 6 Platelet adhesion electron microscope images of the freeze gel prepared in the present application.
[0085] Figure 7 In vivo coagulation results of the freeze gel prepared in the present application.
[0086] Figure 8 ALP and alizarin red detection results of the freeze gel prepared in the present application. DETAILED DESCRIPTION
[0087] The present inventors have found, through extensive and in-depth research, a shape memory freeze gel material with rapid hemostasis and osteogenic repair functions. The present application successfully prepares a multifunctional freeze gel with good formability, rapid liquid absorption and hemostasis ability, excellent biocompatibility and bone tissue induction ability by regulating the synergistic effect of natural high molecular polysaccharide and inorganic nanofiber, supplemented by a crosslinking agent, combined with a freeze forming process.
[0088] The freeze gel described in the present application uses high molecular polysaccharide as the matrix, combined with one-dimensional inorganic nanofiber reinforcement, and its network structure is induced to form a three-dimensional porous structure at low temperature. It can quickly absorb blood and promote blood clot formation while providing an osteogenic microenvironment. The freeze gel can quickly recover its original shape through hydration after compression deformation, has good shape memory performance, and significantly improves its practicality in the process of adapting to complex wound hemostasis and bone defect cavities.
[0089] On this basis, the present application is completed.
[0090] To enable those skilled in the art to understand the features and effects of the present invention, the terms and expressions used in the specification and claims are explained and defined in general below. Unless otherwise specified, all technical and scientific terms used herein have the ordinary meaning understood by those skilled in the art regarding the present invention, and in case of conflict, the definitions in this specification shall prevail.
[0091] In this article, unless otherwise specified, “contains,” “includes,” “containing,” “has,” or similar terms cover the meanings of “composed of” and “mainly composed of,” for example, “A contains a” covers the meanings of “A contains a and others” and “A contains only a.”
[0092] Shape memory cryogel for hemostasis and bone repair In recent years, shape memory cryogels have attracted attention due to their unique three-dimensional porous structure and rapid liquid response. These materials can rapidly recover their original shape after absorbing liquid, effectively filling wounds and binding with blood clots to form a stable barrier, aiding in hemostasis and subsequent tissue repair. Simultaneously, natural cationic polysaccharides possess good biocompatibility, procoagulant activity, and certain antibacterial properties, and can activate platelets and promote blood cell aggregation through electrostatic interactions. Furthermore, combining them with inorganic nanofibers can significantly improve the material's mechanical properties and osteogenic induction capacity.
[0093] Therefore, developing a composite shape memory cryogel constructed from natural polysaccharides and inorganic nanofibers, which combines rapid hemostasis, good mechanical support, and osteogenic promotion properties, is expected to solve the current dual challenges of complex bone hemorrhage treatment and bone tissue repair, and has broad clinical application prospects.
[0094] In view of this, the present invention relates to a multifunctional composite hydrogel, specifically a cryogel with shape memory properties, rapid hemostasis capability and bone tissue repair function, which is suitable for various biomedical applications such as wound repair and bone defect filling.
[0095] This cryogel is formed by cross-linking a polysaccharide aqueous solution, inorganic nanofibers, and a cross-linking agent. More specifically, the cryogel of this invention is prepared using the preparation method described in this invention.
[0096] In the present application, "shape memory hemostatic bone repair integrated frozen gel", "frozen gel", "frozen gel of the present application" are used interchangeably, which refers to the natural high molecular polysaccharide-inorganic nanofiber composite frozen formed gel material in the present application, which has a sponge morphology, and a three-dimensional porous network system with stable structure, rapid liquid absorption response and excellent mechanical properties obtained by adjusting the mass ratio of polysaccharide and inorganic nanofiber and the crosslinking reaction conditions. The frozen gel has the functions of rapid hemostasis and bone repair, effectively solving the technical problems of low hemostatic efficiency, single biological function and insufficient mechanical properties of traditional natural high molecular hemostatic materials.
[0097] The traditional hemostatic bone repair material currently has obvious deficiencies in considering the hemostatic efficiency and osteogenic performance, especially in shape adaptability and biomechanical matching, which is difficult to meet the needs of complex wound surfaces in clinical practice; the present application constructs a nano-enhanced polysaccharide bone repair system by mixing cationic polysaccharide and high aspect ratio inorganic nanofiber; after adding a crosslinking agent, the system forms a frozen gel with a three-dimensional porous structure through freeze-induced phase separation and spatial directional reconstruction, which endows the material with excellent shape memory performance and elastic recovery ability; the polysaccharide skeleton provides the ability to rapidly adsorb blood and platelets, activates the endogenous blood coagulation mechanism, and effectively realizes the immediate plugging of bone bleeding; at the same time, the inorganic nanofiber forms a collagen-like arrangement at the micro level, enhances the mechanical strength and osteogenic differentiation potential of the gel, and provides an inorganic nanofiber template for subsequent bone tissue regeneration; the shape memory composite network constructed by the two in aqueous conditions not only improves the biological stability and conformability of the material, but also has good water retention, prevents rapid dry cracking during the operation, and is beneficial to the operation and molding; through this strategy, the present application realizes the functional integration from hemostasis to bone repair, greatly improving the comprehensive performance of bone wound repair materials.
[0098] The frozen gel of the present application has significant shape memory performance and active procoagulant function, and is suitable for rapid hemostasis treatment in emergency trauma or surgical process. The material can be directly applied to the bleeding site in a compressed and dried state, or injected into a complex wound through a syringe, rapidly absorbs liquid and swells to restore the original shape after contacting blood, thereby achieving physical plugging and shape matching. The cationic groups carried on the surface of the natural high molecular polysaccharide interact with blood components, promote the aggregation of red blood cells and platelets, and activate the coagulation cascade reaction, rapidly forming a blood clot to effectively stop bleeding and prevent rebleeding.
[0099] Firstly, the super-elasticity and shape memory ability of the frozen gel of the present application are derived from the synergistic effect of the ordered porous structure induced by freezing and the chemical cross-linking network. The cross-linking agent can react with the functional groups on the molecular chain of the natural high molecular polysaccharide to form a stable covalent cross-linking structure, thereby constructing a three-dimensional scaffold with elastic ability. During the pressure deformation process, the molecular chain segments can store and release elastic energy, thereby endowing the material with the ability to quickly recover to the original structure under blood contact conditions.
[0100] Secondly, the inorganic nanofiber in the present application not only improves the mechanical strength of the gel, but also has good biological activity. The one-dimensional structure is uniformly distributed in the gel, thereby enhancing the toughness and stability of the overall structure; at the same time, the composition is similar to the inorganic nanofiber component in the natural bone tissue, which can induce the adhesion, proliferation and differentiation of osteogenesis-related cells, and promote the formation of new bone. In combination with the good biocompatibility and degradation performance of the natural high molecular polysaccharide, the overall material has excellent osteogenic repair potential.
[0101] In addition, the raw materials of the frozen gel described in the present application are natural, the preparation process is simple, the obtained material is biodegradable and non-toxic to tissues, the degradation products can be absorbed and utilized by the body, thereby further promoting wound healing. In the medical application scenarios such as hemostasis and bone defect repair, it has a wide clinical transformation prospect.
[0102] In the present application, the inorganic nanofiber and the high molecular polysaccharide form a stable organic-inorganic composite network structure through electrostatic interaction, hydrogen bond, coordination bond or other non-covalent interaction, thereby enhancing the structural stability, biocompatibility and functional performance of the frozen gel.
[0103] The frozen gel material has a three-dimensional porous network structure, and the pore size range is 10-300 μm, preferably 50-200 μm.
[0104] The frozen gel can recover to the original shape within 10 s under the stimulation of liquid such as water or blood, and has a fast response shape memory function.
[0105] The frozen gel has a fast hemostatic performance, is suitable for filling and sealing of the wound site, can absorb exudate liquid and guide blood cell adhesion and platelet activation through the porous structure and surface functional groups thereof, thereby starting the blood coagulation process.
[0106] The frozen gel has good cell compatibility, can promote the adhesion, proliferation and differentiation of osteoblasts, and is suitable for bone tissue defect repair applications.
[0107] The shape memory hemostatic bone repair integrated frozen gel has one or more of the following characteristics: 1) the average pore size of the material is 50-200 μm, preferably 80-120 μm; 2) the porosity of the material is 70%-95%, preferably 90%-95%; 3) the compressive strength of the material is 100-200 kPa, preferably 120-180 kPa; 4) the shape recovery time of the material in blood is 10 s or less, preferably 5 s or less; 5) the shape recovery rate of the material in blood is 80% or more, preferably 90% or more; 6) the material has a recovery loss of no more than 20%, preferably no more than 10%, after 50 cycles of compression; 7) the material has a coagulation index of 20% or less per minute; 8) the material has an adhesion efficiency to blood cells of >50%, preferably >60%; 9) the material has a blood loss of 45%, preferably 30%, in a rat liver penetration wound model hemostasis experiment using medical gelatin hemostatic sponge; 10) the material can significantly promote osteoblast proliferation and differentiation after participating in hemostasis.
[0108] The shape memory frozen gel of the present application has the following advantages compared to existing hemostatic bone repair materials: (1) simple preparation process, wide source of raw materials, low cost, suitable for large-scale production; (2) highly interconnected three-dimensional porous structure is formed by freezing induction, which is beneficial to liquid absorption, cell penetration and tissue regeneration; (3) has rapid shape memory performance, can quickly absorb blood and recover to original shape after compression, tightly fits the wound surface, and realizes effective physical plugging; (4) polysaccharides themselves have natural antibacterial properties, which can help reduce postoperative infection and inflammatory response; (5) shows good osteoblast adhesion and differentiation promotion effect in in vitro experiments, and has the potential to promote bone healing and regeneration.
[0109] Preparation method The preparation method of the frozen gel provided by the present application comprises the following steps: Step one: preparation of inorganic nanofiber reinforced phase: mix the precursor under certain pH conditions, induce the formation of one-dimensional nanostructure by heat treatment (such as hydrothermal or solvothermal), and then wash and dry the obtained product for standby. The inorganic nanofiber phase has good biomineralization induction ability Step two: Preparation of the organic polysaccharide solution: Dissolve the polysaccharide macromolecular material in a suitable solvent system, adjust to a specific concentration and pH condition, and obtain a uniform organic polysaccharide solution.
[0110] Step three: Construction and crosslinking of the composite system: Add the inorganic nanofiber reinforcing component to the polysaccharide solution and uniformly disperse it, then introduce the crosslinking agent to form a precursor solution.
[0111] Step four: Freeze molding and stabilization treatment: Slowly crosslink the precursor solution in a low-temperature environment; further freeze-dry to obtain a freeze gel.
[0112] The amount of inorganic nanofiber added can be adjusted within the range of 10%-100% of the mass of the polysaccharide according to actual performance requirements; the amount of crosslinking agent added is 0.1%-5% of the mass of the polysaccharide, which can be optimized according to the molding strength and biological safety.
[0113] The pore structure of the material can be regulated by the freezing conditions, and the obtained pore size distribution is mainly concentrated between 50-200 μm, which is beneficial for cell infiltration and also helps blood factors to gather and form clots.
[0114] In the preferred embodiments of the present application, a freezing process with lower temperature (e.g. below -20°C) and longer time (more than 12 hours) is used to achieve a stable sponge-like structure and excellent absorption recovery ability.
[0115] According to the above method, in step one, the precursor used includes but is not limited to one or more of inorganic salts such as calcium source, phosphorus source, silicon source, magnesium source, zinc source, titanium source, etc.
[0116] Preferably, in step one, the reaction pH range is 8-11, the reaction temperature is 80-180°C, and the reaction time is 2-24 h, and the heat treatment is preferably hydrothermal treatment.
[0117] Preferably, in step one, the obtained inorganic nanofiber is an inorganic nanofiber with a diameter of 10-100 nm and a length of 0.5-10 μm.
[0118] Preferably, in step two, the polysaccharide is selected from starch, hyaluronic acid, chitosan, sodium alginate, sodium carboxymethyl cellulose, cellulose, or any combination thereof.
[0119] Preferably, in step two, the pH of the organic polysaccharide solution is 3-6, and the concentration is 0.1-5 wt%.
[0120] Preferably, in step three, the crosslinking agent is glutaraldehyde, p-xylylene glycol, dextran aldehyde, or acryloyloxy succinimidyl ester, and the amount added is 0.01-5 wt% of the mass of the organic phase.
[0121] Preferably, in step three, the mass ratio of the polysaccharide to the inorganic nanofiber reinforced component is 1:0.1-1:0.5.
[0122] Preferably, in step four, the freezing temperature is -10°C to -40°C, the freezing time is 12-48 h, and the subsequent drying method is selected from atmospheric drying, vacuum drying or freeze-drying treatment.
[0123] Preferably, the present application provides a preparation method of an integrated freeze gel with shape memory, hemostatic and bone repair functions, comprising the following steps: (1) mixing a high molecular polysaccharide solution and an inorganic nanofiber dispersion solution according to a mass ratio of 1:0.1-1:0.3 to obtain a uniform mixture; (2) adding a crosslinking agent to the mixture and reacting under suitable conditions to form a pre-crosslinked network structure, thereby obtaining a freeze gel precursor solution; (3) freezing and crosslinking the freeze gel precursor solution at -10°C to -40°C for 12-48 h, and then freeze-drying to obtain a freeze gel with shape memory performance.
[0124] More preferably, the polysaccharide is one or more of starch, hyaluronic acid, chitosan, sodium alginate, sodium carboxymethyl cellulose or cellulose.
[0125] More preferably, the inorganic nanofiber is a one-dimensional inorganic nanostructure prepared by a hydrothermal reaction method, and the structure has a biomimetic mineralization activity, and the reaction temperature is 140°C-200°C.
[0126] More preferably, the crosslinking agent is selected from glutaraldehyde, p-phenylenedimethylene, dextran aldehyde, acryloyloxy succinimide ester or a combination thereof, and the concentration of the crosslinking agent is 0.01%-5% (w / v).
[0127] More preferably, the polysaccharide solution is obtained by dissolving the high molecular polysaccharide in deionized water or an acidic solution with a pH of 3-6.
[0128] Preferably, a preparation method of a shape memory hemostatic and bone repair integrated freeze gel comprises the following steps: uniformly mixing a polysaccharide solution and an inorganic nanofiber dispersion solution according to a mass ratio, then adding a crosslinking agent, and then freezing and crosslinking at low temperature, followed by freeze-drying to obtain a freeze gel with shape memory performance.
[0129] More preferably, the freeze gel is composed of a polysaccharide aqueous solution, inorganic nanofibers and a crosslinking agent.
[0130] More preferably, the polysaccharide is one or more of starch, hyaluronic acid, chitosan, sodium alginate, sodium carboxymethyl cellulose or cellulose.
[0131] More preferably, the used precursors include but are not limited to inorganic salts such as calcium source, phosphorus source, silicon source, magnesium source, zinc source, titanium source, etc., which can form one-dimensional inorganic nanofibers with one-dimensional nanostructure and biological mineralization activity.
[0132] More preferably, the calcium source includes but is not limited to calcium chloride, calcium nitrate, calcium acetate, the phosphorus source includes but is not limited to sodium phosphate, ammonium phosphate, phosphoric acid and its salts, and the silicon source, magnesium source, etc. can select corresponding inorganic salt precursors.
[0133] More preferably, the polysaccharide solution is prepared by dissolving polysaccharide in deionized water or an acidic solution (pH 3-6).
[0134] More preferably, the hydrothermal temperature of the inorganic nanofiber is 140°C-200°C.
[0135] More preferably, the crosslinking agent is glutaraldehyde, p-phenylenedimethylene, dextran aldehyde, acryloyloxy succinimidyl ester or a combination thereof.
[0136] More preferably, the mass ratio of the polysaccharide solution to the inorganic nanofiber dispersion solution is 1:0.1-1:0.5, the mass fraction of the polysaccharide in the mixed system is 0.1%-5% (w / v), and the concentration of the crosslinking agent is 0.01%-5% (w / v).
[0137] More preferably, the freezing crosslinking temperature is -10°C to -40°C, and the crosslinking time is 12-48h.
[0138] Application The natural high molecular polysaccharide-inorganic nanofiber composite freeze gel of the present application has good shape memory and active procoagulant function, and is suitable for complex wound bleeding scenes such as tissue penetrating injury, bone tissue defect or narrow deep wound. The material can maintain stable morphology after compression and drying, and can be directly placed at the bleeding site when used, and can swell back to the original structure after absorbing blood, so as to achieve effective tamponade, wound closure and accelerated coagulation and hemostasis. The composite gel overcomes the application limitations of traditional natural polysaccharide hemostatic materials such as easy to be washed away, uncontrollable swelling, poor mechanical properties, no procoagulant activity, etc., and shows excellent clinical applicability.
[0139] The experimental results of the present application show that the natural high molecular freeze gel material has significant advantages in rapid coagulation, reduction of bleeding volume and shortening of hemostasis time in hemostasis, and has excellent tissue compatibility, biodegradability and promotion of tissue repair capacity. The inorganic nanofiber introduced in the composition not only enhances the mechanical properties, but also plays a biological function of inducing osteogenesis and tissue regeneration in vivo.
[0140] In addition, the gel system can be used as a controllable release carrier of drugs or growth factors for various medical purposes such as antibacterial wound surface, chronic wound management, bone tissue engineering, etc., and has broad clinical transformation prospects and industrial application value.
[0141] Medical material and application method The present application provides a medical material comprising the freeze gel of the present application and a carrier acceptable in the field of medical materials.
[0142] The term "carrier acceptable in the field of medical materials" refers to one or more compatible solid, semi-solid, liquid fillers which are suitable for human or animal use and must have sufficient purity and sufficiently low toxicity. "Compatibility" refers to the mutual incorporation of the components in the pharmaceutical composition and the active ingredients of the drug without significantly reducing the drug efficacy.
[0143] It should be understood that in the present application, the carrier is not particularly limited and can be selected from commonly used materials in the art, prepared by conventional methods, or purchased from the market. Examples of pharmaceutically acceptable carriers include vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), wetting agents (such as sodium dodecyl sulfate), buffers, transdermal enhancers, stabilizers, antioxidants, preservatives, bacteriostatic agents, pyrogen-free water, etc.
[0144] As an antioxidant, for example, tocopherol and its ester derivatives, ascorbic acid, ascorbic acid stearate, nordihydroguaiaretic acid, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), citric acid, 2-mercaptobenzimidazole, ethylenediaminetetraacetic acid, etc. can be listed. The antioxidant can be used alone or in combination with two or more.
[0145] As a transdermal enhancer, there is no particular limitation as long as it is a compound generally considered to have an absorption-promoting effect on the skin, for example, fatty alcohols such as isostearyl alcohol, fatty acids such as capric acid, fatty acid derivatives such as monolauric acid propylene glycol ester, isopropyl myristate, isopropyl palmitate, lauric acid diethanolamide, etc., glycols such as propylene glycol, polyethylene glycol, etc. can be listed. The transdermal enhancer can be used alone or in combination with two or more.
[0146] There is no particular limitation on the preservative, and as a preferred example, p-oxybenzoic acid ethyl ester, p-oxybenzoic acid propyl ester, p-oxybenzoic acid butyl ester, etc. can be listed. There is no particular limitation on the filler, and as a preferred example, calcium carbonate, magnesium carbonate, silicates (aluminum silicate, calcium silicate, magnesium silicate, etc.), cellulose derivatives (hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, etc.) can be listed.
[0147] The main advantages of the present application include: Shape memory ability: rapid recovery of initial morphology in dry or compressed state when encountering water, suitable for different topographical defects; High liquid absorption and hemostatic performance: with multi-level pore structure, can quickly absorb blood components and promote hemostatic response; Good biocompatibility and bone repair potential: the natural polymer and biomimetic inorganic nanofiber nanocomponents used have cell adhesion and osteoinductive ability.
[0148] Synergistic mechanism of hemostasis and bone formation: the material of the present application can not only achieve rapid hemostasis, but also regulate the microenvironment of blood clots and activate platelets to release growth factors, thereby achieving synergistic promotion of hemostasis and bone repair in the same system; Regenerative microenvironment construction ability: the present application forms a stable scaffold in situ at the damage site through shape memory and porous biomimetic structure, not only maintains the initial blood clot structure to promote hemostasis, but also continuously provides a bioactive microenvironment required for osteogenesis and angiogenesis, achieving integration of wound repair and tissue regeneration; The preparation process of the present application does not require high-temperature sintering, toxic chemical treatment or complex molds, and the process is mild, facilitating large-scale production and clinical promotion.
[0149] The present application will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present application and not to limit the scope of the present application. The experimental methods in the following examples are generally carried out under conventional conditions, or under conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are weight percentages and weight parts.
[0150] The following examples use conventional equipment in the art. The experimental methods in the following examples are generally carried out under conventional conditions, or under conditions recommended by the manufacturer. In the following examples, various raw materials are used, unless otherwise specified, conventional commercially available products are used, and the specifications are conventional specifications in the art. In the specification of the present application and the following examples, unless otherwise specified, "%" means weight percent, "parts" means weight parts, and the ratio means weight ratio.
[0151] Example 1 Preparation of shape memory hemostatic and bone repair integrated frozen gel according to the present application In this embodiment, hyaluronic acid is used as the matrix material, glutaraldehyde is used as the crosslinking agent, and inorganic nanofiber precursors are used as calcium and phosphorus sources. The specific preparation method is as follows: (1) Preparation of inorganic nanofiber: 12 mL of methanol and 21 mL of oleic acid were mixed, stirred for 10 min, and then slowly added to 27 mL of deionized water to form a milky mixed solution. 2.1 g of NaOH was added, and stirring was continued for 30 min to adjust the pH value. Then NaH2PO4·2H2O solution (1.872 g, 24 mL) and CaCl2 solution (0.66 g, 36 mL) were added dropwise, respectively, and stirred uniformly, and then transferred to a stainless steel high-pressure reaction kettle, and reacted at 160 ℃ for 24 h. The obtained product was collected by centrifugation, and washed with ethanol and deionized water for 3 times alternately, and dried at 60 ℃, to obtain a milky white inorganic nanofiber powder.
[0152] (2) Preparation of a frozen gel precursor solution: 1 g of hyaluronic acid was dissolved in 100 mL of deionized water to form a transparent and uniform solution with a concentration of 1% (w / v), and the pH of the solution was adjusted to 5.5. 0.2 g of inorganic nanofiber was ultrasonically dispersed and then slowly added to the above solution, and then 50 mg of glutaraldehyde was added as a crosslinking agent, and stirred uniformly to form a precursor solution, wherein the concentration of the crosslinking agent glutaraldehyde in the precursor solution was 0.05% (w / v).
[0153] (3) Freeze forming: the precursor solution was injected into a mold, and frozen at -20 ℃ for 24 h to form a three-dimensional porous structure of a frozen gel precursor.
[0154] (4) Freeze drying: the frozen gel was placed in a vacuum freeze drying device for drying for 48 h to obtain a freeze-dried frozen gel.
[0155] Example 2 Preparation of a shape memory hemostatic bone repair integrated frozen gel according to the present application In this embodiment, chitosan is used as a matrix material, and p-phenylenediamine is used as a crosslinking agent. Inorganic nanofiber precursor is used as a representative calcium and silicon source. The specific preparation method is as follows: (1) Preparation of inorganic nanofiber: 15 mL of methanol and 20 mL of oleic acid were mixed, stirred uniformly, and then added dropwise to 30 mL of deionized water to form a milky solution. 2 g of NaOH was added, and stirring was continued for 30 min, and then CaCl2 solution (0.66 g, 30 mL) and Na2SiO3 solution (1.2 g, 20 mL) were added dropwise, respectively, and stirred uniformly, and then transferred to a reaction kettle, and reacted at 180 ℃ for 12 h. The product was washed and dried to obtain a white inorganic nanofiber powder.
[0156] (2) Preparation of the freeze gel precursor solution: 1 g of chitosan was dissolved in 100 mL of acetic acid (1% (w / v)) solution, and the pH of the solution was adjusted to 5.5. 0.3 g of the inorganic nanofiber described above was uniformly dispersed by ultrasonic treatment, and then 100 mg of terephthaldehyde was added as a crosslinking agent, and the concentration of the crosslinking agent was 1% (w / v). The solution was stirred to form a precursor solution.
[0157] (3) Freeze forming: the precursor solution was placed in a mold and frozen at -40 °C for 12 h to obtain a freeze gel precursor.
[0158] (4) Freeze drying: the precursor was dried in a vacuum freeze dryer for 72 h to obtain a porous freeze gel.
[0159] Example 3 Preparation of the shape memory hemostatic and bone repair integrated freeze gel according to the present application In this example, starch is used as the matrix material, dextran aldehyde is used as the crosslinking agent, and the inorganic nanofiber precursor is used as the calcium and magnesium source. The specific preparation method is as follows: (1) Preparation of inorganic nanofiber: 10 mL of methanol and 25 mL of oleic acid were mixed and stirred for 10 min, and then added to 30 mL of deionized water to form an emulsion. 1.8 g of NaOH was added to adjust the pH value, and then Ca(NO3)2 solution (0.72 g, 25 mL) and MgCl2 solution (0.3 g, 20 mL) were added, and the mixture was stirred uniformly and then placed in a reaction kettle and reacted at 150 °C for 18 h. The obtained product was centrifuged, washed and dried to obtain a light white nanofiber powder.
[0160] (2) Preparation of the freeze gel precursor solution: 1 g of starch was dissolved in 100 mL of deionized water, and the pH of the solution was adjusted to 5. After cooling to room temperature, 0.25 g of the nanofiber was added and dispersed by ultrasonic treatment, and then dextran aldehyde was added and stirred uniformly to form a precursor solution. The concentration of the crosslinking agent dextran aldehyde in the precursor solution was 0.05% (w / v).
[0161] (3) Freeze forming: the precursor solution was frozen at -30 °C for 24 h to obtain a freeze gel precursor.
[0162] (4) Freeze drying: the precursor was dried in a freeze drying device for 48 h to obtain a porous freeze gel.
[0163] Example 4 Preparation of the shape memory hemostatic and bone repair integrated freeze gel according to the present application In this example, sodium alginate is used as the matrix material, acryloyloxy succinimidyl ester is used as the crosslinking agent, and the inorganic nanofiber precursor is used as the calcium and titanium source. The specific preparation method is as follows: (1) Preparation of inorganic nanofiber: 12 mL of methanol and 18 mL of oleic acid were mixed, stirred uniformly, and then added to 25 mL of deionated water to obtain an emulsion. 2 g of NaOH was added to adjust the pH value, and then Ca(CH3COO)2 solution (0.6 g, 20 mL) and TiCl4 solution (0.5 g, 20 mL) were added. After being mixed thoroughly, the mixture was placed in a reaction kettle and reacted at 170 °C for 20 h. The obtained product was washed and dried to obtain off-white inorganic nanofiber.
[0164] (2) Preparation of a frozen gel precursor solution: 1 g of sodium alginate was dissolved in 100 mL of deionized water, and the pH of the solution was adjusted to 5.5. Then, 0.2 g of the above-mentioned nanofiber was uniformly dispersed by ultrasonic, and acryloyloxy succinimidyl ester was added to form a uniform precursor solution. The concentration of the crosslinking agent acryloyloxy succinimidyl ester in the precursor solution was 0.2% (w / v).
[0165] (3) Freeze forming: The precursor solution was poured into a mold and frozen at -25 °C for 18 h to obtain a frozen gel precursor.
[0166] (4) Freeze drying: The precursor was vacuum freeze-dried for 60 h to obtain a porous frozen gel.
[0167] Example 5 Preparation of a shape memory hemostatic bone repair integrated frozen gel according to the present application In this example, sodium carboxymethyl cellulose was used as a base material, glutaraldehyde was used as a crosslinking agent, and inorganic nanofiber precursor was used as a calcium-zinc source. The specific preparation method is as follows: (1) Preparation of inorganic nanofiber: 10 mL of methanol and 20 mL of oleic acid were mixed, stirred for 10 min, and then added to 30 mL of deionized water to form an emulsion. 1.5 g of NaOH was added and stirred uniformly, and then CaCl2 solution (0.6 g, 30 mL) and Zn(NO3)2 solution (0.4 g, 20 mL) were added dropwise. After being stirred uniformly, the mixture was transferred into a reaction kettle and reacted at 160 °C for 24 h. The obtained product was washed and dried to obtain light yellow nanofiber powder.
[0168] (2) Preparation of a frozen gel precursor solution: 1 g of sodium carboxymethyl cellulose was dissolved in 100 mL of deionized water, and the pH of the solution was adjusted to 5.5. Then, 0.2 g of the above-mentioned nanofiber was dispersed by ultrasonic, and glutaraldehyde was added for crosslinking. After being stirred uniformly, a precursor solution was obtained. The concentration of the crosslinking agent glutaraldehyde in the precursor solution was 0.05% (w / v).
[0169] (3) Freeze forming and drying: The precursor solution was frozen at -20 °C for 24 h, and then dried in a freeze dryer for 48 h to obtain a porous frozen gel.
[0170] Example 6 Preparation of shape memory hemostatic bone repair integrated cryogel according to the present application This example takes chitosan / hyaluronic acid complex as the base material, terephthaldehyde as the crosslinking agent, and inorganic nanofiber precursor as the calcium-phosphorus-silicon source. The specific preparation method is as follows: (1) Preparation of inorganic nanofiber: 12 mL of methanol and 18 mL of oleic acid were mixed, stirred uniformly, and then added to 25 mL of deionized water. 2 g of NaOH was added to adjust the pH. Then Ca(NO3)2 solution (0.5 g, 20 mL), NaH2PO4 solution (0.6 g, 20 mL), and Na2SiO3 solution (0.5 g, 20 mL) were added dropwise. The mixture was placed in a reaction kettle and reacted at 170°C for 16 h. After washing and drying, the off-white ternary composite nanofiber was obtained.
[0171] (2) Preparation of cryogel precursor solution: 0.5 g of chitosan was dissolved in 100 mL of 2% acetic acid aqueous solution, and the pH of the solution was adjusted to 5.5. Then 0.5 g of hyaluronic acid solution was added, and the mixture was stirred uniformly. Then 0.3 g of ternary nanofiber was added and uniformly dispersed by ultrasonic. Then terephthaldehyde was added for crosslinking, and the mixture was stirred to obtain the precursor solution. The concentration of terephthaldehyde crosslinking agent in the precursor solution was 0.1% (w / v).
[0172] (3) Freeze forming and drying: The precursor solution was frozen at -30°C for 18 h, and then vacuum freeze-dried for 72 h to obtain the porous cryogel.
[0173] Example 7 Preparation of shape memory hemostatic bone repair integrated cryogel according to the present application This example takes sodium alginate / starch complex as the base material, dextran aldehyde as the crosslinking agent, and inorganic nanofiber precursor as the calcium-magnesium-silicon source. The specific preparation method is as follows: (1) Preparation of inorganic nanofiber: 15 mL of methanol and 20 mL of oleic acid were mixed, stirred uniformly, and then added to 30 mL of deionized water to form an emulsion. 2 g of NaOH was added and stirred uniformly, and then CaCl2 solution (0.5 g, 20 mL), MgCl2 solution (0.4 g, 20 mL), and Na2SiO3 solution (0.6 g, 20 mL) were added dropwise in sequence. The mixture was transferred to a reaction kettle and reacted at 180°C for 20 h to obtain light-colored nanofiber.
[0174] (2) Preparation of the freeze gel precursor solution: 0.5 g of sodium alginate and 0.5 g of starch were dissolved in 100 mL of deionized water, mixed uniformly, and the pH of the solution was adjusted to 5; 0.25 g of the above-mentioned nanofiber was added after ultrasonic dispersion, and dextran aldehyde crosslinking was added, stirred uniformly, to obtain the precursor solution, wherein the concentration of the dextran aldehyde crosslinking agent in the precursor solution was 0.05% (w / v).
[0175] (3) Freeze forming and drying: the precursor solution was frozen at -25 °C for 24 h, and then dried in a freeze dryer for 60 h to obtain a porous freeze gel.
[0176] Example 8 Microstructure of the freeze gel The microstructure of the freeze gel obtained in Example 6 was observed by scanning electron microscopy (SEM). The obtained image is shown in Figure 1 From the figure, it can be seen that the surface of the obtained freeze gel presents a uniform three-dimensional interconnected porous structure, the pore size distribution is uniform, the structure is loose, and it embodies good liquid permeability and cell invasion ability, which is helpful for the application of the material in hemostasis and tissue repair.
[0177] Example 9 Water-triggered shape memory performance of the freeze gel The freeze gel described in Example 2 was prepared into a cylinder with a diameter of 5 mm and a height of 10 mm, compressed to the minimum height and kept for 5 min, then placed in water to observe the shape recovery process, and the recovery height and time were recorded. The shape recovery rate (%) was expressed by the ratio of the recovery height to the original height, and the response speed was expressed by the time required for recovery. The results are shown in Figure 2 The figure shows that the freeze gel can quickly recover to the initial shape in 3 seconds after being triggered by water, with high shape recovery rate and short response time, indicating that the material has excellent water-triggered shape memory performance and is suitable for rapid response scenarios such as hemostasis.
[0178] Example 10 Blood-triggered shape memory performance of the freeze gel The test method was the same as in Example 9, and whole blood was used as the trigger medium instead of water to evaluate the shape memory response ability in a blood environment. The results are shown in Figure 3 As can be seen from the figure, the freeze gel also exhibits rapid shape recovery ability in a blood environment, indicating that the material also has excellent dynamic response performance in a real physiological environment, which is conducive to the immediate hemostatic function of the material in actual bleeding scenarios.
[0179] Example 11 In vitro and in vivo biocompatibility of the freeze gel BMSCs were seeded in 48-well plates at a density of 10,000 cells / well and allowed to adhere for 12 h. Subsequently, all the frozen gels with a diameter of 5 mm and a length of 1 mm were immersed in culture medium. After 1, 3 and 5 days, the viability of BMSCs in contact with the frozen gels was quantitatively analyzed by CCK-8 assay.
[0180] A 1 cm incision was made on the back of the rats and the frozen gel samples were implanted into the incisions. After 7 and 14 days, the rats were euthanized and the tissues in contact with the implants were collected. The collected samples were fixed in 4% paraformaldehyde, embedded in paraffin and sectioned, and the potential inflammatory response was analyzed using H&E staining.
[0181] The frozen gels prepared in Example 7 were used as an example, Figure 4 The results of the in vitro and in vivo biocompatibility of the frozen gels. In the in vitro cell viability test, the frozen gels showed a good cell proliferation trend after co-culturing with BMSCs; in the animal implantation experiment, the HE staining results showed that there was no obvious inflammatory response in the surrounding tissues, confirming that the material has good cell compatibility and tissue adaptability.
[0182] Example 12 Red blood cell adhesion ability of the frozen gels 50 μL of RBC suspension was dropped onto the surface of the frozen gels, and after incubation at 37 °C for 5 min, the sample surface was washed with PBS to remove the unadhered RBCs. Subsequently, the frozen gels were transferred to 5 mL of deionized water and kept for 1 h to completely dissolve the red blood cells adhered to the frozen gels. The absorbance of the solution was measured at 540 nm using a microplate reader. The absorbance value after mixing 50 μL of RBC suspension with 5 mL of deionized water was taken as the control value. The percentage of adhered RBCs was calculated by the following formula: RBC (%) = (OD sample / OD control) x 100% At the same time, the adhered red blood cells were fixed with 2.5% (v / v) glutaraldehyde for 2 h, and then dehydrated with 50%, 60%, 70%, 80%, 90% and 100% ethanol solutions at 5 min intervals. Acetyl isoamyl was added for 1 h replacement reaction. The adhesion of red blood cells on the dried samples was observed using field emission scanning electron microscopy (FE-SEM).
[0183] The frozen gels prepared in Example 5 were used as an example, Figure 5 The results of the red blood cell adhesion of the frozen gels, and medical gelatin sponge was used as a positive control. From the red blood cell adhesion quantitative results and electron microscopy observation, it can be seen that the frozen gel surface has obvious adhesion ability to red blood cells, showing good blood cell affinity, which helps to quickly enrich blood cells and promote the occurrence of hemostatic response. At the same time, the three-dimensional pore structure on the surface of the gel provides effective adsorption sites for blood cells.
[0184] Example 13 Platelet adhesion ability of the frozen gel Platelet-rich plasma (PRP) was obtained from citrate whole blood by centrifugation at 1500 rpm for 10 min. Subsequently, 50 μΐ of isolated PRP was dropped onto the frozen gel, and then the sample was incubated at 37 °C for 1 h. All samples were washed with PBS three times to remove the physically adhered platelets, and then immersed in 1% Triton X-100 to lyse the platelets and release lactate dehydrogenase (LDH), and the concentration of LDH was measured using a lactate dehydrogenase assay kit.
[0185] Similarly, the samples were fixed in 2.5% glutaraldehyde and dehydrated with ethanol solution. The morphology of platelet adhesion on the dried frozen gel was observed using FE-SEM, and the steps were the same as those in the red blood cell adhesion assay, which are not repeated here.
[0186] Taking the frozen gel prepared in Example 3 as an example, Figure 6 Medical gelatin sponge was used as a positive control for the platelet adhesion results of the frozen gel. The data in the figure show that the surface of the frozen gel has good adhesion to platelets, and the activated morphology of the platelets, such as the extension of pseudopods, is observed under the electron microscope, indicating that the material can effectively promote platelet activation and aggregation, providing strong mechanism support for its rapid hemostasis.
[0187] Example 14 In vivo coagulation results of the frozen gel The hemostatic properties of the frozen gel were observed using a rat liver defect bleeding model and a rat femoral artery bleeding model. Rats were used for experiments after being fed for one week, and were fasted with water for 24 h before the experiment. The frozen gel was prepared into a cylinder with a diameter of 5 mm and a height of 5 mm.
[0188] Rat liver defect bleeding: The rats were randomly divided into 2 groups, and then deeply anesthetized, the abdomen was incised, and the middle lobe of the liver was exposed. Filter paper was placed under the liver. A circular perforation wound with a diameter of 4 mm was created in the liver to induce bleeding. Then the wound was filled with the frozen gel. The liver without any treatment served as a blank control group, and medical gelatin sponge served as a positive control.
[0189] Rat femoral artery bleeding: The rats were randomly divided into 2 groups, and then all of them were anesthetized, and a 3 mm long longitudinal incision was made at the root of the left thigh to expose the blood vessel, and the blood vessel was incised with a scalpel. After bleeding naturally for 3 s, the frozen gel was pressed on the wound and kept for 5 s. The untreated group served as a blank control group, and medical gelatin sponge served as a positive control.
[0190] Taking the frozen gel prepared in Example 1 as an example, Figure 7 In vivo hemostatic results of the frozen gel.
[0191] The data in the figure show that the freeze gel prepared in Example 1 of the present application exhibits excellent hemostatic effect in both bleeding models: In the liver defect bleeding model, the freeze gel can quickly absorb blood and plug the wound. Compared with the medical gelatin sponge (positive control), the freeze gel has equivalent or even better hemostatic effect, and is significantly better than the blank control group (untreated).
[0192] In the femoral artery bleeding model, the freeze gel forms a stable clot in a short time, seals the wound, and quickly stops bleeding, effectively controlling the high pressure bleeding of the artery. It is also superior to the blank control in both hemostatic time and blood loss, and the effect is better than the positive control group.
[0193] These results show that the freeze gel has good rapid hemostatic ability and application stability, and can effectively deal with acute bleeding situations in different parts and types. It has broad application prospects in surgical operations or trauma treatment.
[0194] Example 15 The BMSCs were co-cultured with CSHAn at a density of 1 × 10 4 The cells were co-cultured with CSHAn at a density of 1 × 10
[0195] Taking the freeze gel prepared in Example 1 as an example, Figure 8 The ALP and ARS results of the freeze gel, including the ALP and ARS staining results. ALP staining shows that the freeze gel group has significantly enhanced early osteogenic marker expression, and ARS staining proves that it has a significant advantage in promoting the generation of calcium nodules. The results show that the freeze gel has excellent osteogenic induction performance and potential applications in the field of bone tissue repair.
[0196] Discussion The application discloses a shape memory hemostatic bone repair integrated frozen gel and a preparation method and application thereof. The frozen gel is added with natural high molecular polysaccharide, inorganic nanofiber with bone repair activity and a crosslinking agent in the preparation process, and a shape memory frozen gel with a double network structure is formed through Schiff base reaction and electrostatic interaction. The prepared frozen gel has excellent liquid absorption capacity and mechanical strength, can rapidly rebound and fill a wound after absorbing blood, and realizes efficient physical plugging and hemostasis. Meanwhile, the material can absorb blood cells and platelets, and exhibits enhanced procoagulant activity, and the hemostatic performance is superior to that of traditional gelatin sponge. Further, the frozen gel exhibits good cell compatibility, and can effectively promote bone tissue regeneration by enhancing alkaline phosphatase activity and promoting calcium nodule formation. Therefore, the material has both rapid hemostasis and osteogenic activity, and has a wide clinical application prospect.
[0197] All documents referred to in this application are incorporated herein by reference as if each individual document were specifically and individually incorporated by reference. In addition, it is to be understood that the application may be carried out by specifically different embodiments and that each disclosed embodiment can be implemented with or without the corresponding benefits depending upon the desired results of the implementation.
Claims
1. A method of preparing a frozen gel, characterized in that, The method comprises the following steps: (s1) mixing a polysaccharide solution, inorganic nanofiber and a crosslinking agent to form a cryogel precursor solution; The inorganic nanofiber is prepared by a method comprising: (a) mixing methanol, water and oleic acid to form a milky mixed solution, then mixing with an alkali to adjust the pH value, and then adding a precursor to perform a hydrothermal reaction to obtain the inorganic nanofiber; (s2) performing a freeze crosslinking on the cryogel precursor solution obtained in step (s1) at low temperature to obtain a cryogel precursor; (s3) performing a freeze drying on the cryogel precursor obtained in step (s2) to obtain the cryogel.
2. The production method according to claim 1, wherein The inorganic nanofiber is selected from the group consisting of hydroxyapatite nanowire, silicate nanowire, zirconia nanowire, titanate nanowire, magnesium-based nanowire, zinc-based nanowire, or a combination thereof.
3. The production method according to claim 1, wherein In step (a), the precursor is an inorganic salt precursor selected from the group consisting of a calcium source, a phosphorus source, a silicon source, a magnesium source, a zinc source, a titanium source, a zirconium source, or a combination thereof; The calcium source is selected from the group consisting of calcium chloride, calcium nitrate, calcium acetate, or a combination thereof; The phosphorus source is selected from the group consisting of sodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, ammonium phosphate, diammonium hydrogen phosphate, ammonium dihydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, or a combination thereof; The silicon source is selected from the group consisting of sodium silicate, potassium silicate, or a combination thereof; The magnesium source is selected from the group consisting of magnesium chloride, magnesium nitrate, magnesium bromide, magnesium acetate, or a combination thereof; The titanium source is selected from the group consisting of titanium chloride, sodium hexafluorotitanate, potassium hexafluorotitanate, titanyl sulfate, or a combination thereof; The zinc source is selected from the group consisting of zinc chloride, zinc sulfate, zinc nitrate, zinc perchlorate, zinc gluconate, zinc acetate, or a combination thereof; The zirconium source is selected from the group consisting of zirconium chloride, zirconium oxychloride, zirconium nitrate, zirconium citrate, zirconium lactate, or a combination thereof.
4. The production method according to claim 1, wherein The polysaccharide in the polysaccharide solution is selected from the group consisting of starch, hyaluronic acid, chitosan, sodium alginate, sodium carboxymethyl cellulose, carboxymethyl cellulose, or a combination thereof.
5. The production method according to claim 1, wherein In step (s1), the crosslinking agent is selected from the group consisting of glutaraldehyde, p-phenylenedimethylene, dextran aldehyde, acryloyloxy succinimidyl ester, or a combination thereof.
6. The production method according to claim 1, wherein In step (s1), the mass fraction of the polysaccharide in the cryogel precursor solution is 0.1%-5% (w / v); and / or In step (s1), the ratio of the polysaccharide to the inorganic nanofiber is 1:0.1-1:1 (w / w); and / or In step (s1), the mass fraction of the crosslinking agent in the cryogel precursor solution is 0.01%-1% (w / v).
7. A cryogel prepared by the method of any one of claims 1-6.
8. The frozen gel of claim 7, wherein, In the cryogel, the polysaccharide, the inorganic nanofiber and the crosslinking agent form an interpenetrating network with each other.
9. A medical material, characterized by The medical material comprises the cryogel of claim 7.
10. Use of the cryogel according to claim 7 or the medical material according to claim 9 for the production of a material, characterized in that, The material (a) is used for hemostasis; and / or (b) is used for bone tissue defect repair; and / or (c) is used as a controllable release carrier of drugs or growth factors.
